Intravenous Adenosine is indicated for the following: Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome).

Dosage & Administration

Initial dose: 6 mg given as rapid IV bolus (administered over 1-2 second period). Repeat administration: If the first dose does not result in elimination of the supraventricular tachycardia within 1-2 minutes, 12 mg should be given as rapid intravenous bolus. This 12 mg dose may be repeated for second time if required.
Pediatric patients: The dosages used in neonates, infants, children and adolescents were equivalent to those administered to adults on a weight basis. Pediatric patients with a body weight < 50 kg: Initial dose - 0.05 to 0.1 mg/kg as a rapid IV bolus given either centrally or peripherally. A saline flush should follow. Repeat administration: If conversion of PSVT does not occur within 1-2 minutes, additional bolus injections of adenosine can be administered at incrementally higher doses, increasing the amount given by 0.05 to 0.1 mg/kg. A saline flush should follow. This process should continue until sinus rhythm is established or a maximum single dose of 0.3 mg/kg is used. Pediatric patients with a body weight > 50 kg: The adult dose is recommended. Doses greater than 12 mg are not recommended for adult and pediatric patients.


Use in Pregnancy: Since it is not known whether Adenosine can cause fetal harm when administered to pregnant women, Adenosine should be used during pregnancy only if clearly needed.

Product Details

Related Products


Cardiovascular Products


Cardiovascular Products

Preclot AS

Clopidogrel & Aspirin
Cardiovascular Products


Cardiovascular Products


Enoxaparin Sodium
Cardiovascular Products